EMERYVILLE, Calif., April 3 /PRNewswire-FirstCall/ -- Bionovo, Inc.
(Nasdaq: BNVI), a leader in the discovery and development of safe and
effective drugs in the areas of women's health and cancer, is scheduled to
present at the Cambria Capital Investor Meeting in Salt Lake City on April 9,
2009 at 3:45 p.m. MST.
Mary Tagliaferri, M.D., President and Chief Medical Officer, is scheduled
to present. The purpose of the presentation will be to update investors on the
current business developments and goals.
No webcast or archive will be available for this presentation. All
interested parties wishing to attend should contact Cambria Capital at (877)
224-0477 toll free, (801) 320-9606 main or by email at
About Cambria Capital, LLC
Cambria Capital, LLC ("Cambria") is an investment banking and securities
brokerage firm with offices in Salt Lake City, Los Angeles and San Francisco.
Cambria's mission is to facilitate the growth and development of promising
companies at all stages of development by providing capital and a wide variety
of financial advisory services. The financing arranged by Cambria originates
from a number of sources, including the firm's principals and Cambria's
network of high net-worth individuals and institutional investors. Cambria
employs a number of corporate finance structures, including PIPEs (Private
Investments in Public Equities), private placements of equity and debt
securities and reverse mergers. Cambria is a member of the Financial Industry
Regulatory Authority, Inc. ("FINRA"), and the Securities Investor Protection
Corporation (SIPC). Visit the Cambria website at
About Bionovo, Inc.
Bionovo is a pharmaceutical company focused on the discovery and
development of safe and effective treatments for women's health and cancer,
markets with significant unmet needs and billions in potential annual revenue.
The company applies its expertise in the biology of menopause and cancer to
design new drugs derived from botanical sources which have novel mechanisms of
action. Based on the results of early and mid-stage clinical trials, Bionovo
believes they have discovered new classes of drug candidates within their rich
pipeline with the potential to be leaders in their markets. Bionovo is
headquartered in Emeryville, California and is traded on the NASDAQ Capital
Market under the symbol, "BNVI". For more information about Bionovo and its
programs, visit: http://www.bionovo.com.
This release contains certain forward-looking statements relating to the
business of Bionovo, Inc. that can be identified by the use of forward-looking
terminology such as "believes," "expects," or similar expressions. Such
forward-looking statements involve known and unknown risks and uncertainties,
including uncertainties relating to product development, efficacy and safety,
regulatory actions or delays, the ability to obtain or maintain patent or
other proprietary intellectual property protection, market acceptance,
physician acceptance, third party reimbursement, future capital requirements,
competition in general and other factors that may cause actual results to be
materially different from those described herein as anticipated, believed,
estimated or expected. Certain of these risks and uncertainties are or will be
described in greater detail in our filings with the Securities and Exchange
Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under
no obligation (and expressly disclaims any such obligation) to update or alter
its forward-looking statements whether as a result of new information, future
events or otherwise.
Company Contacts: Investor Contacts:
Claire Fong Joe Diaz, Robert Blum
Tom Chesterman Joe Dorame
Tel: 510.601.2000 Lytham Partners, LLC
email@example.com Tel: 602.889.9700
SOURCE Bionovo, Inc.
/CONTACT: Claire Fong or Tom Chesterman, both of Bionovo, Inc.,
+1-510-601-2000, firstname.lastname@example.org; or Joe Diaz, Robert Blum or Joe Dorame,
all of Lytham Partners, LLC, +1-602-889-9700, email@example.com, for
/Web Site: http://www.bionovo.com /
CO: Bionovo, Inc.; Cambria Capital, LLC
ST: California, Utah
IN: MTC HEA
SU: TDS WOM
-- LA94608 --
7758 04/03/2009 19:20 EDT http://www.prnewswire.com